Plug Power Inc vs 10X Genomics Inc — how do they compare? Plug Power Inc trades at $1.75 (market cap $2.49B), while 10X Genomics Inc trades at $80.1 (market cap $9.92B). The key difference: 10X Genomics Inc is far larger — about 4× Plug Power Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plug Power Inc for 41 Days and 10X Genomics Inc for 92 Days on average.
| PLUG | TXG | |
|---|---|---|
Market Cap | $2.49B | $9.92B |
Volume | 47,846,349 | 9,372,166 |
Sector | Industrials | Health |
52-Week High | $4.14 | $97.74 |
52-Week Low | $1.73 | $11.48 |
Typical Hold Time | 41 Days | 92 Days |
Enterprise Value | $3.36B | $9.44B |
Signals from Pluang's Aura AI — not financial advice
Plug Power (PLUG) trades at $1.78, down 4.3% today, with a bearish technical outlook and negative earnings momentum. The company continues to report significant losses with a net income margin of -220.59% and negative cash flow, though recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels. Analyst consensus shows mixed sentiment with 44.7% buy ratings and a $3.13 price target, representing 76% upside potential from current levels.
While PLUG shows potential through hydrogen infrastructure expansion and recent contract wins, the investment case remains high-risk due to persistent negative profitability, cash burn, and competitive pressures. The stock trades near analyst low targets, suggesting limited downside protection, making it suitable only for speculative investors comfortable with substantial volatility and execution risk in the clean energy sector.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →